News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Promedior Announces Presentation of Preclinical Data at AASLD Demonstrating that Pentraxin-2 Suppresses Liver Fibrosis


11/2/2011 8:41:59 AM

MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA. The data to be presented highlight the efficacy and utility of Pentraxin-2 in suppressing fibrosis and providing a clear hepatoprotective effect in independent models of liver fibrosis. In liver fibrosis, Pentraxin-2 inhibits the activation of monocytes, fibrocytes and hepatic stellate cells. Promedior’s lead product, PRM-151, is a recombinant form of the naturally circulating human protein Pentraxin-2, which has been shown to regulate the cell populations that control fibrosis, inflammation and pathologic neovascularization.

Read at BioSpace.com

comments powered by Disqus
Promedior
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES